Home Business Cue Biopharma, Inc. (NASDAQ:CUE) stock surged in the current trading session; here’s...

Cue Biopharma, Inc. (NASDAQ:CUE) stock surged in the current trading session; here’s why

In the current trading session, at the last check, the CUE stock had surged by 29.88% to $14.62. CUE’s stock previously closed at $11.26. The CUE stock volume traded 7.72 million shares. The average trade volume for 3 months was 281.11K. The company is valued at $332.51 million and has 30.30 million outstanding shares.

Cue announces positive report for PR in ongoing Phase 1 Monotherapy Study of CUE-101

Today on 10th May 2021, the company reported interim clinical data, including an affirmed halfway reaction (PR), from its continuous Phase 1a/1b monotherapy investigation of CUE-101 as second-line treatment for patients with HPV+ R/M HNSCC. Until this point, CUE-101 has shown a great bearableness profile in a monotherapy portion heightening preliminary and keenly encourages new datasets to its pharmacokinetic (PK) and pharmacodynamic (PD) profiles, just as clinical anti-tumor action.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Key interval investigation of patient information from the ongoing open-label Phase 1a/1b examination includes; Affirmed PR in one patient and SD in five patients, all affirmed by RECIST measures, in the portion heightening period of the investigation to date, giving early indications of potential single-specialist movement of CUE-101. The investigations demonstrated proof of both tumor-explicit CD8+ T cell extensions just as portion subordinate expansions in NK cells in patients.

The study detected safe cell penetration and tumor cell necrosis in patient tumor biopsies after CUE-101 treatment, supporting CUE-101’s system of activity at drawing in and balancing focused on T cells inside the patient’s body. Furthermore, dose-proportional PK profile and similar medication exposure levels in patients getting continued dosing cycles, steady with an absence of medication clearing against drug antibodies. The experiments resulted in no most extreme endured portion (MTD) saw in patients dosed with up to 8 mg/kg of CUE-101.

The road ahead for the clinical action of CUE-101

Accepting early affirmation of clinical action of CUE-101 as a monotherapy in this difficult patient populace is a significant approval of the capability of the CUE-101 program for oncology. CUE stock expects various significant achievements over time with the capability of additional information to illuminate CUE-101’s clinical application.

These achievements incorporate, the likely choice of a suggested Phase 2 portion of CUE-101 by mid-2021 as stated by the company, for additional improvement as a solitary specialist treatment for HPV+ 2L+ head and neck squamous cell carcinoma. The company plans to report introductory Phase 1 outcome from the mix investigation of CUE-101 with pembrolizumab in the second 50% of 2021 and furthermore plans to start a Phase 2 neoadjuvant study to assess the impacts of CUE-101 on the tumor microenvironment, which is likewise expected to begin in the second 50% of 2021.

About Prompt Bipharma Inc.

Prompt Biopharma, Inc., is a biopharmaceutical organization that specifically focuses on creating biological medications for the particular adjustment of the human immune system framework to treat a scope of tumors, persistent irresistible sicknesses, and immune system issues. The organization was once in the past known as Imagen Biopharma, Inc. what’s more, changed its name to Cue Biopharma, Inc. in October 2016. Sign Biopharma, Inc. was established in 2014 and is settled in Cambridge, Massachusetts.

The organization offers CUE-102, an oncofetal viral antigen for tumors, including strong tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 system that incorporates CD80 or potentially 4-1BBL to reactivate depleted T cells and configuration to improve antigen-explicit T cell for the therapy of constant irresistible illnesses; and CUE-300 structure to target different immune system infections.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

Smith Micro Develops Inc. (SMSI) stock soars during current market trading. Here’s to know why?

Smith Micro Develops Inc. (NASDAQ: SMSI) stock surged by 2.39% during the current market trading session. Smith Micro creates software that simplifies and improves...

Drive Shack Inc. (DS) stock soars during after-hour trading, followed by no recent update

Drive Shack Inc. (NASDAQ: DS) stock declined by 3.94% at last close while the DS stock-price surged by 7.38% in the after-hour session. Drive...

SPX Flow Inc. (FLOW) stock surged during current market. Here’s why the stock is sky-rocketing?

SPX Flow Inc. (NASDAQ: FLOW) stock gained by 24.24% in the current market trading session. SPX FLOW, based in Charlotte, works to make the...

Platinum Group Metal Ltd. (PLG) stock surges during after-market trading. Here’s to know what’s happening?

Platinum Group Metal Ltd. (NASDAQ: PLG) stock declined by 8.54% at last close whereas the PLG stock price gains by 7% in the after-market...

TD Holdings Inc. (GLG) stock gains during current market trading. Here’s the recent update

TD Holdings Inc. (NASDAQ: GLG) stock gains by 5.01% in the current market trading session. TD Holdings, Inc. is a service provider in China...

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

NeuroMetrix Inc. (NURO) stock plunged during pre-market. Let’s find out why?

NeuroMetrix Inc. (NASDAQ: NURO) stock gained by 18.89% at last close while the NURO stock price losses by -4.12% in the pre-market trading session....

Related News

PaySign, Inc. (PAYS) Stock Down Following Disclosure of Troubling Q1 2021 Financial Reports

PaySign, Inc. (PAYS) stock prices were down 15.0568% early in the trading day on May 12th, 2021, bringing the price per share down to...

Nano-X Imaging Ltd. (NASDAQ: NNOX) stock fall during current market. Here’s to know why?

Nano-X Imaging Ltd. (NASDAQ: NNOX) stock declines by 12.41% in the current market trading after NNOX released its first-quarter 2021 financial results. Nanox, an...

International Game Technology PLC (IGT) Stock Trending Up Following Promising Q1 2021 Financial Reports

International Game Technology PLC (IGT) stock prices were up by 4.76% shortly after market trading commenced on May 11th, 2021, bringing the price per...

Phunware Inc. (NASDAQ:PHUN) stock surged in the current trading session; here’s why

In the current trading session, at the last check, PHUN stock had surged by 12.31% to $1.38. PHUN stock previously closed session at $1.23....

Conformis, Inc. (CFMS) Stock Trending Up Following 510(k) Clearance from FDA for Identity Imprint

Conformis, Inc. (CFMS) stock prices were up 5.9061% during the first half of the trading day on May 10th, 2021, bringing the price per...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam